Comparative Acute Systemic Toxicity of Several Quinoxaline 1,4-Di-N-oxides in Wistar Rats

Abstract The acute toxicity of six quinoxaline 1,4-di-N-oxides has been evaluated in an attempt to determine: a) the feasibility of testing systemic toxicity of these compounds in a very preliminary phase without an adequate formulation for in vivo administration, b) the LD50 range and the toxic target organ of these compounds in order to have an approximation of the structure-activity relationship. Quinoxaline 1,4-di-N-oxides have shown a great variety of biological activities with potential therapeutic application in cancer, malaria, etc. Problems of toxicity hinder the progression of these compounds to clinical phases. The compounds dissolved in DMSO at their solubility limit were administered i.V. to female Wistar rats (8 weeks, 160 g), using an infusion pump (300 µL; 20 µl/min). Animals were observed for a period of 14 days. This dose of the vehicle (1.7 ml/kg) was well tolerated by the animals. The LD50 could not be determined, but a marked hypoactivity was induced by the treatment. The same compounds were also injected intraperi-toneally, suspended in 0.01 % Tween 80/0.09% saline, and the animals that did not die were observed for a period of 14 days. The LD50 could be estimated to be in a range between 30 and 120 mg/kg, except for one of the compounds. A decrease in the evolution of body weight and hypoactivity were the principal symptoms induced by the treatment. In both assays, histopathologic study of heart, liver, kidney, lung, spleen and ovaries indicated that the target organs may be heart and spleen. In conclusion, the i.V. route is not adequate for estimating the LD50 of these compounds due to solubility problems; by i.p. route, the LD50 interval is between 30 and 120 mg/kg. The data did not permit the deduction of any specific structure-activity relationship.

[1]  H. G. Vogel Guidelines for the Care and Use of Laboratory Animals , 2007 .

[2]  I. White,et al.  Acute lesions in rats caused by 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) or nitromin: a comparison with rates of reduction in microsomal systems from target organs , 2006, Archives of Toxicology.

[3]  P. Corona,et al.  Quinoxaline 1,4-dioxide: a versatile scaffold endowed with manifold activities. , 2005, Current medicinal chemistry.

[4]  A. Costa-Filho,et al.  Novel Cu(II) quinoxaline N1,N4-dioxide complexes as selective hypoxic cytotoxins. , 2005, European journal of medicinal chemistry.

[5]  S. Cannas,et al.  In vitro activity of new quinoxalin 1,4-dioxide derivatives against strains of Mycobacterium tuberculosis and other mycobacteria. , 2005, International journal of antimicrobial agents.

[6]  H. Cerecetto,et al.  Quinoxaline N,N'-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships. , 2004, Bioorganic & medicinal chemistry letters.

[7]  H. Gali-Muhtasib,et al.  Quinoxaline 1,4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation. , 2004, International journal of oncology.

[8]  S. Zanetti,et al.  Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-substituted-6,7-difluoro-3-methylquinoxaline 1,4-dioxides. , 2004, European journal of medicinal chemistry.

[9]  S. Irwin,et al.  Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse , 1968, Psychopharmacologia.

[10]  E. Essassi,et al.  [Synthesis and pharmacological study of three 1-alkyl-3-(ethoxycarbonylmethylene)-2-oxo quinoxalines]. , 2002, Annales Pharmaceutiques Françaises.

[11]  S. Zanetti,et al.  Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity. , 2002, European journal of medicinal chemistry.

[12]  H. Gali-Muhtasib,et al.  Quinoxaline 1,4‐dioxides: Hypoxia‐selective therapeutic agents , 2002, Molecular carcinogenesis.

[13]  A. Monge,et al.  Anti-Mycobacterium tuberculosis Agents Derived from Quinoxaline-2-carbonitrile and Quinoxaline-2-carbonitrile 1,4-di-N-oxide , 2002, Arzneimittelforschung.

[14]  H. Gali-Muhtasib,et al.  Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs. , 2001, Oncology reports.

[15]  A. López de Cerain,et al.  New quinoxalinecarbonitrile 1,4-di-N-oxide derivatives as hypoxic-cytotoxic agents. , 2000, European journal of medicinal chemistry.

[16]  B. Wouters,et al.  Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin , 1999, British Journal of Cancer.

[17]  A. López de Cerain,et al.  Synthesis and antituberculosis activity of new 2-quinoxalinecarbonitrile 1,4-di-N-oxides. , 1999, Die Pharmazie.

[18]  A. López de Cerain,et al.  New Quinoxaline 1,4-Di-N-oxides for Treatment of Tuberculosis , 1999, Arzneimittelforschung.

[19]  N. Sodir,et al.  Photoprotective effects of some quinoxaline 1,4-dioxides in hairless mice , 1998, Medical oncology.

[20]  A. López de Cerain,et al.  Synthesis and antituberculosis activity of some new 2-quinoxalinecarbonitriles. , 1998, Farmaco.

[21]  A. López de Cerain,et al.  Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. 2. , 1995, Journal of medicinal chemistry.

[22]  E. Clarke,et al.  Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides. , 1995, Journal of medicinal chemistry.

[23]  M. Naylor Novel N-oxides as bioreductive drugs. , 1994, Oncology Research.

[24]  M. Haddadin,et al.  The Beirut Reaction , 1993 .

[25]  S. Zanetti,et al.  2-Phenyl-6(7)-R-substituted quinoxalines N-oxides. Synthesis, structure elucidation and antimicrobial activity , 1990 .

[26]  M. Lemmon,et al.  Structure-activity relationships for benzotriazine di-N-oxides. , 1989, International journal of radiation oncology, biology, physics.

[27]  L. Chappel,et al.  Pyridoquinoxaline N-oxides. 1. A new class of antitrichomonal agents. , 1982, Journal of medicinal chemistry.

[28]  B. Dominy,et al.  Synthesis and antibacterial activity of 1-hydroxy-1-methyl-1,3-dihydrofuro[3,4-b]quinoxaline 4,9-dioxide and related compounds. , 1979, Journal of medicinal chemistry.

[29]  J. Dirlam,et al.  Synthesis and antibacterial activity of isomeric 6- and 7-acetyl-3-methyl-2- quinoxalinecarbozamide 1,4-dioxides. , 1978, Journal of medicinal chemistry.

[30]  W. Suter,et al.  Mode of Action of Quindoxin and Substituted Quinoxaline-di-N-Oxides on Escherichia coli , 1978, Antimicrobial Agents and Chemotherapy.

[31]  C. O. Knowles Chemistry and toxicology of quinoxaline, organotin, organofluorine, and formamidine acaricides. , 1976, Environmental health perspectives.

[32]  G. Sponer,et al.  Acute toxicity of various solvents in the mouse and rat. LD50 of ethanol, diethylacetamide, dimethylformamide, dimethylsulfoxide, glycerine, N-methylpyrrolidone, polyethylene glycol 400, 1,2-propanediol and Tween 20. , 1976, Arzneimittel-Forschung.